Lower Urinary Tract Symptoms
Patients who underwent the minimally invasive procedure had a 36%, 50%, and 44% improvement in IPSS, quality of life, and peak flow rate, respectively, at 5 years.
Long-term use of the drug may predispose men to worsening erectile dysfunction and elevated risk of diabetes and non-alcoholic fatty liver disease.
PUL involves placement of small permanent metallic implants into the prostate that lift the lateral lobes away from the urethra and remove obstruction.
In a study, 81.1% of men were able to void after an average of 28 days after treatment.
Patients' pre-existing urinary problems influenced their perceptions of symptom relief after prostate cancer treatment.
Study documents significant improvements in frequency, urgency, and nocturia.
Three quarters of patients experienced significant improvements in lower urinary tract symptoms and quality of life observed and were satisfied with treatment.
Men receiving common medical treatments for LUTS/BPH, including phytotherapy, experienced similar symptom relief.
The risk is 67% higher in men with a prostate size of 40.1-80 mL than those with smaller glands.
The risk of bladder outlet obstruction increased 34% per unit increase in serum PSA and decreased 23% per unit increase in maximal flow rate.
A recent review found little evidence to support severe lower urinary tract symptoms as a contraindication to TRT.
Use of high-velocity saline streams show promise in a small, first-in-man study.
Prostatic urethral lift is minimally invasive and, according to a new study, the procedure's beneficial effects are durable out to 3 years.
Overall, men with LUTS showed remarkably poor knowledge about their symptoms.
Men who reported having severe lower urinary tract symptoms (LUTS) had a 64% increased risk of the malignancy compared with those who reported no LUTS.
Vancouver Symptom Score linked to bullying victimization and perpetrator scores
Metabolic syndrome linked to severity of LUTS; symptoms improve after bariatric surgery
Sitting to urinate is associated with an improved urodynamic profile in lower urinary tract symptoms (LUTS).
Many urologists not uniformly adhering to AUA guidelines for the management of benign prostatic hyperplasia/lower urinary tract symptoms.
Men with diabetic peripheral neuropathy have an increased occurrence of erectile dysfunction and lower-urinary-tract symptoms.
Only 10% of men aged 45-69 years who progress from no or mild to moderate or severe lower urinary tract symptoms are treated, study finds.
Compared with standing, sitting was associated with significantly lower post-void residual volume.
Ejaculatory function worsens, however, in men taking 5 alpha-reductase inhibitors.
Range of risk factors identified for incidence and remission of ED, dyadic and solitary sexual desire.
About 30 percent of men experience an AUA symptoms index improvement of 3 or more points.
Improvements observed in urinary symptoms and bone mineral density.
Men with a body mass index of 30 kg/m2 or higher had a 39.3% prevalence of low testosterone, study finds.
Significant declines in International Prostate Symptom Score observed, regardless of whether or not men lost weight or used a phosphodiesterase-5 inhibitor.
Desmopressin appears to reduce nocturia and other LUTS while also significantly increasing testosterone levels in late-onset hypogonadism.
Study results underscore the need for additional research to find other surrogate markers of urinary infection.
Renal and Urology News Articles
- For Treating Uremic Pruritus, Evidence is Strongest for Gabapentin
- IgG-Degrading Enzyme Desensitizes, Permits HLA-Incompatible Transplant
- Evaluating Practice Options in the Shifting Health Care Landscape
- Not All High-Risk Prostate Cancers Are the Same
- Active Surveillance for Intermediate-Risk PCa May Be Unsafe
Sign Up for Free e-newsletters
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)